Last reviewed · How we verify

NCT06043024

Characteristics of Cytokine Response in Patients With Temporomandibular Disorders Treated With Occlusal Splint Therapy

Completed NA Last updated 19 September 2024
What this trial tests

NA trial testing Stabilization occlusal splint in Temporomandibular Joint Disorders in 36 participants. Completed in 16 August 2024.

Timeline
16 August 2023
Primary endpoint
16 August 2024
16 August 2024

Quick facts

Lead sponsorJosip Juraj Strossmayer University of Osijek
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment36
Start date16 August 2023
Primary completion16 August 2024
Estimated completion16 August 2024
Sites1 location across Croatia

Drugs / interventions tested

Conditions studied

Sponsor

Josip Juraj Strossmayer University of Osijek

Who can join

Adults 18 to 65, any sex, with Temporomandibular Joint Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this intervention study is to determine the effect of occlusal splint (OS) therapy on the concentration of inflammatory cytokines in serum and gingival crevicular fluid (GCF) in patients with temporomandibular disorders (TMDs). Aims are: * to determine cytokines level in GCF and serum before and after OS therapy * to determine the degree of psychosocial dysfunction and oral health-related quality of life before and after OS therapy * investigate the correlation between cytokines level in GCF and serum * to determine the effect of OS on treatment outcomes, pain intensity, dysfunction, and psychosocial status of patients with painful TMD. Participants will be asked to complete self-assessment questionnaires, and GCF and blood samples will be collected before beginning of the OS therapy and at follow-up examinations one month and two months after.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Stabilization Splint Therapy for Patients with Temporomandibular Disorders Improves Opening Movements and Jaw Limitation and Attenuates Pain by Influencing the Levels of IL-7, IL-8, and IL-13 in the Gingival Crevicular Fluid.
    Sikora R, Duspara K, Matić A, Petrović A, et al · · 2025 · cited 1× · PMID 40142185 · DOI 10.3390/medicina61030375

Verify or expand the search:

Other recruiting trials for Temporomandibular Joint Disorders

Currently open trials in the same condition.

Other Josip Juraj Strossmayer University of Osijek trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06043024.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing